Glycation, Nutrition and Metabolism Laboratory, Department of Diabetes, Central Clinical School, Monash University, Melbourne 3004, Australia.
Baker Heart & Diabetes Institute, Melbourne 3004, Australia.
Nutrients. 2022 Oct 28;14(21):4547. doi: 10.3390/nu14214547.
Diabetes is the leading cause of kidney disease, and as the number of individuals with diabetes increases there is a concomitant increase in the prevalence of diabetic kidney disease (DKD). Diabetes contributes to the development of DKD through a number of pathways, including inflammation, oxidative stress, and the gut-kidney axis, which may be amenable to dietary therapy. Resistant starch (RS) is a dietary fibre that alters the gut microbial consortium, leading to an increase in the microbial production of short chain fatty acids. Evidence from animal and human studies indicate that short chain fatty acids are able to attenuate inflammatory and oxidative stress pathways, which may mitigate the progression of DKD. In this review, we evaluate and summarise the evidence from both preclinical models of DKD and clinical trials that have utilised RS as a dietary therapy to limit the progression of DKD.
糖尿病是导致肾脏疾病的主要原因,随着糖尿病患者人数的增加,糖尿病肾病(DKD)的患病率也随之增加。糖尿病通过多种途径导致 DKD 的发生,包括炎症、氧化应激和肠道-肾脏轴,这些途径可能可以通过饮食治疗来改善。抗性淀粉(RS)是一种膳食纤维,它可以改变肠道微生物群落,导致短链脂肪酸的微生物产量增加。来自动物和人体研究的证据表明,短链脂肪酸能够减轻炎症和氧化应激途径,从而可能减缓 DKD 的进展。在这篇综述中,我们评估和总结了 DKD 临床前模型和临床试验的证据,这些研究都使用 RS 作为饮食疗法来限制 DKD 的进展。